These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 28582422)

  • 21. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LRRK2 Modulates the Exocyst Complex Assembly by Interacting with Sec8.
    Fais M; Sanna G; Galioto M; Nguyen TTD; Trần MUT; Sini P; Carta F; Turrini F; Xiong Y; Dawson TM; Dawson VL; Crosio C; Iaccarino C
    Cells; 2021 Jan; 10(2):. PubMed ID: 33498474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.
    Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK
    Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease.
    Nguyen M; Krainc D
    Proc Natl Acad Sci U S A; 2018 May; 115(21):5576-5581. PubMed ID: 29735704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2.
    Belluzzi E; Greggio E; Piccoli G
    Biochem Soc Trans; 2012 Oct; 40(5):1111-6. PubMed ID: 22988874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory.
    Beccano-Kelly DA; Volta M; Munsie LN; Paschall SA; Tatarnikov I; Co K; Chou P; Cao LP; Bergeron S; Mitchell E; Han H; Melrose HL; Tapia L; Raymond LA; Farrer MJ; Milnerwood AJ
    Hum Mol Genet; 2015 Mar; 24(5):1336-49. PubMed ID: 25343991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LRRK2 functions as a scaffolding kinase of ASK1-mediated neuronal cell death.
    Yoon JH; Mo JS; Kim MY; Ann EJ; Ahn JS; Jo EH; Lee HJ; Lee YC; Seol W; Yarmoluk SM; Gasser T; Kahle PJ; Liu GH; Belmonte JCI; Park HS
    Biochim Biophys Acta Mol Cell Res; 2017 Dec; 1864(12):2356-2368. PubMed ID: 28888991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
    Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
    J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parkinson's-linked LRRK2-G2019S derails AMPAR trafficking, mobility, and composition in striatum with cell-type and subunit specificity.
    Gupta S; Tielemans A; Guevara CA; Huntley GW; Benson DL
    Proc Natl Acad Sci U S A; 2024 Jul; 121(28):e2317833121. PubMed ID: 38968112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission.
    Qin Q; Zhi LT; Li XT; Yue ZY; Li GZ; Zhang H
    CNS Neurosci Ther; 2017 Feb; 23(2):162-173. PubMed ID: 27943591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions.
    Carrion MDP; Marsicano S; Daniele F; Marte A; Pischedda F; Di Cairano E; Piovesana E; von Zweydorf F; Kremmer E; Gloeckner CJ; Onofri F; Perego C; Piccoli G
    Sci Rep; 2017 Jul; 7(1):5377. PubMed ID: 28710481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular functions of LRRK2 implicate vesicular trafficking pathways in Parkinson's disease.
    Cookson MR
    Biochem Soc Trans; 2016 Dec; 44(6):1603-1610. PubMed ID: 27913668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluctuation Imaging of LRRK2 Reveals that the G2019S Mutation Alters Spatial and Membrane Dynamics.
    Sanstrum BJ; Goo BMSS; Holden DZY; Delgado DD; Nguyen TPN; Lee KD; James NG
    Molecules; 2020 May; 25(11):. PubMed ID: 32486414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice.
    Palomo-Garo C; Gómez-Gálvez Y; García C; Fernández-Ruiz J
    Pharmacol Res; 2016 Aug; 110():181-192. PubMed ID: 27063942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson's disease.
    Liu HF; Ho PW; Leung GC; Lam CS; Pang SY; Li L; Kung MH; Ramsden DB; Ho SL
    Sci Rep; 2017 Jan; 7():40887. PubMed ID: 28098219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The LRRK2 N-terminal domain influences vesicle trafficking: impact of the E193K variant.
    Marku A; Carrion MDP; Pischedda F; Marte A; Casiraghi Z; Marciani P; von Zweydorf F; Gloeckner CJ; Onofri F; Perego C; Piccoli G
    Sci Rep; 2020 Mar; 10(1):3799. PubMed ID: 32123243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
    Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
    Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VPS35 regulates cell surface recycling and signaling of dopamine receptor D1.
    Wang C; Niu M; Zhou Z; Zheng X; Zhang L; Tian Y; Yu X; Bu G; Xu H; Ma Q; Zhang YW
    Neurobiol Aging; 2016 Oct; 46():22-31. PubMed ID: 27460146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson's disease.
    Iovino L; Giusti V; Pischedda F; Giusto E; Plotegher N; Marte A; Battisti I; Di Iacovo A; Marku A; Piccoli G; Bandopadhyay R; Perego C; Bonifacino T; Bonanno G; Roseti C; Bossi E; Arrigoni G; Bubacco L; Greggio E; Hilfiker S; Civiero L
    Acta Neuropathol; 2022 Jul; 144(1):81-106. PubMed ID: 35596783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ULK1 and JNK are involved in mitophagy incurred by LRRK2 G2019S expression.
    Zhu Y; Wang C; Yu M; Cui J; Liu L; Xu Z
    Protein Cell; 2013 Sep; 4(9):711-21. PubMed ID: 27023913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.